Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT01903668 Withdrawn - Sepsis Clinical Trials

Determination of the Nature of the Endogenous Ligand of TREM-1 and Its Use as a New Diagnostic Biomarker in Sepsis

Start date: April 2012
Phase: N/A
Study type: Observational

Step 1: Identification and characterisation of the TREM1L protein from samples already available characterised at the hospital Central of Nancy Step 2: Study of the isoforms of TREM1L in correlation with the prognosis of sepsis, Step 3: implementation of assay methods for TREM1L (ELISA or SUPRA MS) Step 4: Validation of assays for TREM1L and its isoforms in a larger number of subjects (inclusion of samples from Dijon CHU and Besançon CHU)

NCT ID: NCT01825421 Withdrawn - Clinical trials for Neonatal Late-onset Sepsis

A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64

Start date: October 2014
Phase: N/A
Study type: Interventional

Unnecessary and prolonged antibiotic therapy in newborn babies can have serious consequences including development of necrotizing enterocolitis (a serious, potentially life-threatening gastrointestinal illness in premature babies), late-onset infections, resistance to antibiotics, increased length of hospital stay, and death. Starting and continuing antibiotic therapy for blood culture-negative infections in the neonatal intensive care unit (NICU) is fairly common with numbers of such patients varying from 20%-90% of infants undergoing a sepsis evaluation in the NICU. While blood culture results are the gold standard, there is usually a delay of up to 48-72h before the results are known. Hence, initiation and continuation of antibiotic treatment are usually based on clinical evaluation and blood count criteria which do not possess high specificity or sensitivity, and may be unreliable in the first few hours after birth or in the early stages of infection. Since the investigators found that neutrophil CD64 (a type of protein found on the surface of a type of white blood cell that can be detected quickly in a very small amount of blood sample) has high accuracy for early detection of blood culture-proven infections in newborn babies, with extremely high negative predictive value (can identify babies definitively with no infection), the investigators will use this test to decide whether to stop or continue antibiotics in the NICU. The investigators hypothesis is that neutrophil CD64 values can be safely used to discontinue antibiotics in newborns suspected of having infections. The investigators aims are to utilize sequential measurements of CD64 values to stop antibiotics early in neonates being investigated for both early and late-onset infections in the NICU. This is a prospective, randomized, controlled (RCT) trial. The study population will be derived from the sub-set of all newborn infants who have undergone investigations for presence of infection in the NICU.

NCT ID: NCT01801020 Withdrawn - Sepsis Clinical Trials

Different Modes of Temperature Measurement in the Emergency Department

Start date: March 2013
Phase: Phase 3
Study type: Interventional

Introduction: Temperature measurement is a crucial and integral element in the assessment of the emergency department patients. The basis of triage and treatment is often directly influenced by temperature measurement. The finding of hyper/hypothermia may differentiate between a simple urinary tract infection and pyelonephritis, or in more extreme cases may discern "weakness" in the elderly from sepsis. This brief encounter of temperature measurement may be paramount to the medical treatment of the emergency department patient. The investigators will explore the different modes of temperature measurements in emergency department patients.

NCT ID: NCT01723501 Withdrawn - Neonatal Sepsis Clinical Trials

Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing <1500 g at Birth

CAPS
Start date: November 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Purpose of this study is determine if skin application of chlorhexidine at birth would reduce infection in infants weighing <1500 g at birth.

NCT ID: NCT01601938 Withdrawn - Sepsis Clinical Trials

Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients

SEREAL
Start date: September 2012
Phase: Phase 2
Study type: Interventional

This study will be performed to determine whether selenium replacement reduces 28-day mortality of severe sepsis and septic shock patients, and to investigate whether selenium replacement contributes differently to the mortality reduction of the patients according to their initial serum selenium level.

NCT ID: NCT01573806 Withdrawn - Inflammation Clinical Trials

Pharmacology of Exenatide in Pediatric Sepsis

PEPS
Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Pharmacology of Exenatide in Pediatric Sepsis, PEPS is a phase 1-2 research study that will examine drug safety, drug metabolism, drug action and preliminary drug clinical effects of four does of exenatide injected every 12 hours to children with shock from infection (septic shock). The investigators hypothesize that exenatide can be safely dosed to children with sepsis to achieve blood levels of drug similar to that achieved in teenagers with type 2 diabetes. The investigators further hypothesize that injection of exenatide to children with septic shock will normalize blood glucose levels and decrease levels of inflammation proteins in the blood during the early course of sepsis.

NCT ID: NCT01505478 Withdrawn - Sepsis Clinical Trials

Comparing an Automated to a Conventional Sepsis Clinical Prediction Rule

Start date: July 2012
Phase: N/A
Study type: Observational

The investigators will conduct a prospective cohort study to compare an automated sepsis severity score to a conventional clinical prediction rule to risk stratify patients admitted from the emergency department (ED) with suspected infection for 28 day in-hospital mortality.

NCT ID: NCT01472952 Withdrawn - Sepsis Clinical Trials

System-level Monitoring of Immune Activation Concerning Susceptibility to Sepsis in Trauma Patients

Start date: February 2012
Phase: N/A
Study type: Observational

Sepsis remains a common entity in critical care patients with remarkable mortality. Despite extended research activities, no reliable bio-markers or scoring systems attributing the individual risk of developing sepsis have been found so far. Patients with multiple trauma are at high risk of developing sepsis. Due to local and systemic immune reactions, high plasma levels of known pro-inflammatory cytokines can be found. Simultaneously, certain anti-inflammatory reactions such as changes in immune cell activity and serum cytokine levels, known as "compensatory anti-inflammatory response syndrome" (CARS) take place. In addition to changes of cytokine levels and immune cell activity, underlying genetic reactions are present. For instance, expression of miRNA (as an potential important step of immune cell activation) is likely changed during systemic and local immune reactions. In the present study levels of pro- and antiinflammatory cytokines, a detailed assay of immune cell activation and the various expression of miRNA will be evaluated in patients of multiple trauma on day 1 and day 4. Additionally, clinical parameters of organ function, current infection markers as CRP and Procalcitonin, cardiovascular function such as Indocyanin clearance and hemodynamic measures delivered with PiCCO-system and heart rate variability will be assessed. Parameters of local tissue perfusion will be measured with transcutaneous laser doppler.

NCT ID: NCT01409772 Withdrawn - Clinical trials for Short Bowel Syndrome

Evaluation of 70% Ethanol Lock Solution to Prevent Catheter Related Blood Stream Infections in Pediatric Patients

Start date: May 2009
Phase:
Study type: Observational

The purpose of this study is to evaluate the clinical practice of the prophylactic use of ethanol locks for the prevention of catheter related blood stream infections in pediatric intestinal rehabilitation program patients requiring total parenteral nutrition.

NCT ID: NCT01382394 Withdrawn - Heart Failure Clinical Trials

Impact of Clinical, Demographic and Laboratory Variables on Brain Natriuretic Peptide Levels

Start date: July 2009
Phase: N/A
Study type: Observational

Brain natriuretic peptide (BNP) is involved in the regulation of blood pressure and fluid volume. It is used for the early diagnosis of heart failure (HF) in patients presenting to the emergency room with dyspnea. Interleukin-6 (IL-6) is a cytokine marker of inflammation that exhibits significant prognostic value in predicting severity and outcome of sepsis. Recently, it was suggested that inflammatory cytokines play an important role in the development of heart failure. Procalcitonin (PCT) is a propeptide of calcitonin which is normally produced in the C-cells of the thyroid glands. Although physiologic levels of PCT remain very low, a dramatic increase in serum PCT levels is observed during severe systemic infections. These properties make procalcitonin less useful for the diagnosis of simple infections but a very promising marker of severe infections especially in the critical care setting. To investigate the co-relation between BNP, IL-6 and procalcitonin in two groups of patients; those presenting with the diagnosis of decompensated heart failure and in patients presenting with the diagnosis of sepsis without cardiovascular or hemodynamic dysfunction.